Self-Inactivating MMLV Vector with CMV Enhancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Moloney murine leukemia virus (MMLV) gene therapy vectors face challenges such as the risk of proto-oncogene activation, interference with internal promoters, and reduced vector stability due to the presence of long terminal repeats (LTRs), which can lead to tumorigenesis and decreased transduction efficiency.
Innovation Solution
A self-inactivating MMLV vector design is developed, where the nucleic acid fragment between the PvuII and SacI enzyme recognition sites in the U3 region of both 5' and 3' LTRs is modified to include a CMV enhancer and promoter, and a polyadenylation signal sequence is added to the 3' end of the 3' LTR, eliminating CAAT boxes and enhancing virus titer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional MMLV vector with wild-type LTRs is used, then high transduction efficiency and stable integration are achieved, but the risk of proto-oncogene activation and tumorigenesis increases
Solution Approach 1:
The patent removes the U3 region (containing CAAT box and enhancer sequences) from the 3' LTR to eliminate the harmful promoter/enhancer activity that causes proto-oncogene activation, while preserving the essential LTR structure for integration. This extraction of the dangerous element resolves the contradiction between maintaining transduction efficiency and eliminating tumorigenesis risk.
Solution Approach 2:
The patent converts the potentially harmful LTR structure into a beneficial self-inactivating design by deleting the U3 region in the 3' LTR. This modification ensures that after reverse transcription and integration, the resulting provirus has defective LTRs that cannot activate proto-oncogenes, while still allowing efficient transduction and stable integration to occur.
2Reliability
If U3 region is deleted in 3' LTR to reduce proto-oncogene activation risk, then safety is improved, but virus titer and expression efficiency decrease
Solution Approach 1:
The patent applies different modifications to the 5' and 3' LTRs: the 5' LTR retains its wild-type structure with full promoter and enhancer activity to ensure high virus production, while the 3' LTR has the U3 region deleted to eliminate safety risks. This local differentiation resolves the contradiction by allowing high titer production in one location while ensuring safety in another.
3Duration of action of stationary object
If wild-type LTRs are retained in MMLV vector, then stable integration and long-lasting expression are achieved, but vector stability decreases due to homologous recombination
Solution Approach 1:
The patent creates asymmetric LTR structures where the 5' LTR remains wild-type and the 3' LTR is modified with U3 deletion. This asymmetry prevents homologous recombination between identical LTR sequences while maintaining the functional benefits of LTR-mediated integration and long-term expression.
Data Source
AI summary
Provided are a Moloney murine leukemia virus-based self-inactivating vector and applications thereof. The self-inactivating vector comprises: 5′LTR, a target expression gene or multiple cloning sites used for inserting the target expression gene, 3′LTR, and a polyadenylated nucleic acid fragment, where the nucleic acid fragment between the Pvu II enzyme cutting site and the Sac I enzyme cutting site of the U3 region of 5′LTR is replaced by a CMV enhancer and a CMV promoter connected to the CMV enhancer, the nucleic acid fragment between the Pvu II enzyme cutting site and the Sac I enzyme cutting site of the U3 region of 3′LTR is deleted, and the polyadenylated nucleic acid fragment is located at the 3′-terminus of 3′LTR. The self-inactivating vector, serving as a vector for a gene therapy, provides increased safeness and a high virus titer, and allows the high-efficiency expression of a target gene.